David König

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 12

Top Topics

Diffuse Large B Cell Lymphoma

Acute Lymphoblastic Leukemia

Systematic Review

Rheumatoid Arthritis Patients

Top Venues

Journal for immunotherapy of cancer

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
David König, Michael T Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth Artemis Kappos, Dirk J Schaefer, Christoph Kettelhack, Jakob R Passweg, Andreas Holbro, Katharina Baur, Michael Medinger, Andreas S Buser, Didier Lardinois, Lukas T Jeker, Nina Khanna, Frank Stenner, Benjamin Kasenda, Krisztian Homicsko, Matthias S Matter, Natalia Rodrigues Mantuano, Alfred Zippelius, Heinz Laubli
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes. Cancer immunology research 12 (7) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
David König, Michael T Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth Artemis Kappos, Dirk J Schaefer, Christoph Kettelhack, Jakob R Passweg, Andreas Holbro, Katharina Baur, Michael Medinger, Andreas S Buser, Didier Lardinois, Lukas T Jeker, Nina Khanna, Frank Stenner, Benjamin Kasenda, Krisztian Homicsko, Matthias S Matter, Natalia Rodrigues Mantuano, Alfred Zippelius, Heinz Laubli
Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes. Cancer immunology research (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Laubli
Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for immunotherapy of cancer 12 (1) (2024)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 11 (11) (2023)